quicker to function then Viagra, Cialis and Levitra

Vivus Inc is celebrating after the results from the phase three clinical trial of avanafil produced excellent results. They said that three-quarters of impotent men who were given either 100mg or 200mg of the drug were able to have sexual intercourse and that almost 60 percent were able to continue until climax. Vivus said that the drug worked fast and that it was quicker to function then Viagra, Cialis and Levitra.

This trial is the first of three phase 3 clinical trials being done to satisfy Food & Drug Administration requirements and it is likely that an official application for approval will be done toward the end of 2010. The stock market reacted well to the results of the trial with a more than nine percent increase in share price reported. In all 650 men took part in this trial which was undertaken with a placebo controlled, double blind and randomised format.

According to the chief executive of Vivus, Leland Wilson, Viagra reaches its maximum strength after one hour, Cialis gets to maximum after two hours but the new avanafil drug gets there after 35 minutes.  Mr. Wilson also said that men wanted to get erect “sooner rather than later”, and thus this drug would have a useful application. No significant side effects were reported except for the usual ones seen with all PDE-5 inhibitors, namely facial flushing and mild headaches.

The way that we see it at Ukmedix News is that all of the erectile dysfunction drugs are effective and safe but that some men just prefer one over the other. For example Cialis is often preferred because it lasts for so much longer than Viagra and Levitra but some men just swear by the other two and say that they get better erections with them. Avanafil is also likely to have its fans.

Vivus which is based in California has also been making headlines because of its new weight loss medication Qnexa that has also been producing statistically significant weight loss and it is likely that this drug will also be soon filing for FDA approval.